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Abstract
Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone
receptor ligands that exert clinically relevant tissue-selective progesterone agonist, antagonist,
partial, or mixed agonist/antagonist effects on various progesterone target tissues in an in vivo
situation depending on the biological action studied. The SPRM asoprisnil is being studied in women
with symptomatic uterine leiomyomata and endometriosis. Asoprisnil shows a high degree of
uterine selectivity as compared to effects on ovulation or ovarian hormone secretion in humans. It
induces amenorrhea and decreases leiomyoma volume in a dose-dependent manner in the
presence of follicular phase estrogen concentrations. It also has endometrial antiproliferative
effects. In pregnant animals, the myometrial, i.e. labor-inducing, effects of asoprisnil are blunted or
absent. Studies in non-human primates played a key role during the preclinical development of
selective progesterone receptor modulators. These studies provided the first evidence of uterus-
selective effects of asoprisnil and structurally related compounds, and the rationale for clinical
development of asoprisnil.
Background
Progesterone plays a crucial role in controlling various
reproductive functions. It is the natural ligand of the pro-
gesterone receptor (PR), which is expressed in various tis-
sues in the body, predominantly in the reproductive tract.
The isolation of progesterone in 1934 [1-3] led to the
search for synthetic, orally active progestins (PR agonists)
that have found broad applications in fertility control and
hormone therapy. Since the discovery of mifepristone in
1981 by the scientists of Roussel Uclaf [4], several proges-
terone antagonists (PAs) became available for preclinical
and clinical evaluation [5]. More recently, selective pro-
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thesized and biologically characterized. SPRMs represent
a new class of PR ligands that exert clinically relevant tis-
sue-selective progesterone agonist, antagonist, partial, or
mixed agonist/antagonist effects on various progesterone
target tissues in an in vivo situation depending on the bio-
logical action studied [6]. Asoprisnil (J867), a novel ster-
oidal compound that belongs to the class of 11β-
benzaldoxime-substituted estratrienes [7,8], is being stud-
ied in women with symptomatic uterine leiomyomata
and endometriosis. It shows high PR specificity, mixed PR
agonist/antagonist activity, and high degree of uterine
selectivity in animal models and humans [8]. Unlike PAs,
asoprisnil does not induce labor in relevant models of
pregnancy and parturition.
Studies in cynomolgus monkeys provided the first evi-
dence that the 11β-benzaldoxime-substituted SPRMs may
induce amenorrhea by directly targeting the endometrium
and have direct endometrial antiproliferative effects, irre-
spective of ongoing ovulatory cycles [9]. The endometrial
effects of SPRMs and PAs are specific to menstruating pri-
mates (Old World monkeys, humans) since variable
effects were observed in non-menstruating species
(rodents, rabbits, tree shrews, and New World monkeys)
[9]. The endometrial antiproliferative effects and the
endometrium specific vascular effects were subsequently
confirmed in women treated with asoprisnil [10]. Human
studies also showed that asoprisnil improved the symp-
toms of leiomyomata, reduced leiomyoma volume [11],
and reduced pain associated with endometriosis [12]. In
this brief review, we discuss the discovery and early clini-
cal development of asoprisnil and related SPRMs, focus-
ing on the effects of these compounds on the primate
uterus.
Discovery and early development of 11β-
benzaldoxime-substituted SPRMs
Asoprisnil and structurally related SPRMs (Figures 1 and
2) were identified at EnTec GmbH and Jenapharm GmbH
(Jena, Germany) during a SPRM ('mesoprogestin') drug
discovery program [13]. The aim of this program was to
find PR ligands with mixed PR agonist/antagonist, anti-
proliferative effects on the endometrium, no antigluco-
corticoid effects, and weak or absent abortifacient activity
for treatment of gynecological disorders. The screening
program included a range of receptor binding studies and
a hierarchy of in vivo tests. The selection of candidate
compounds was performed primarily in animal models,
including non-pregnant and pregnant guinea pigs, rab-
bits, rats, and monkeys. The assessment of endometrial
effects was of crucial importance for the final selection of
candidate compounds. This assessment was performed in
cynomolgus and rhesus macaques because the
endometrium of these monkeys shows striking similari-
ties with that of women with respect to hormonal regula-
tion and morphological changes during the menstrual
cycle [14]. Based on the data from animal studies gener-
ated during this program, it was possible to rank the new
SPRMs and the reference compounds according to the
presence and absence of partial PR agonist and antagonist
activities (Figure 3). Compounds with high PR agonist
activity had low abortifacient activity and high ability to
suppress estrogen effects in the uterus [13]. Asoprisnil
(J867) was selected for further development based on its
pronounced PR agonist and endometrial antiproliferative
effects and the absence of labor-inducing activity.
Effect of SPRMs on the primate endometrium
The primate endometrium is a highly specialized tissue
composed of different cell components, including lumi-
nal and glandular epithelium, endometrial stroma, lym-
phoid and non-lymphoid cells, and blood vessels [15].
The endometrium is probably the most dynamic tissue in
the human body. In humans and menstruating ("old-
world") non-human primates the endometrium under-
goes cyclic changes characterized by regeneration and pro-
liferation during the follicular phase of the ovarian cycle,
secretory differentiation during the luteal phase, and men-
struation accompanied by vasoconstriction of spiral arter-
ies and changes in extracellullar matrix that occur after the
physiologic decline in progesterone concentrations that
occur at the end of the luteal phase. Spiral arteries are key
vessels that control menstruation [16]. These vessels are
unique to the primate endometrium and are highly sensi-
tive to progesterone. They seem to be controlled by
perivascular stromal cells (pericytes), which show very
high PR density [17].
Estrogen is the primary mitogen in the endometrium, act-
ing primarily on the epithelium. "Unopposed" estrogen
treatment (without a progestin phase) leads to prolifera-
tion of glandular and stromal cells and may lead to
endometrial hyperplasia and possibly endometrial can-
cer. Endometrial hyperplasia is characterized by increased
proliferation of the endometrial glandular epithelium,
resulting in an increase of the gland/stroma ratio. Proges-
terone and synthetic progestins oppose the effects of
estrogen on the epithelium, and thereby protect the
endometrium from the development of hyperplasia. The
specific mechanisms that have been proposed to explain
the antiproliferative action of progesterone on the uterine
epithelium include: (i) down-regulation of estrogen
receptors (ER) in target tissues, (ii) induction of the
endometrial enzyme 17β-hydroxysteroid dehydrogenase
Type 2 that catalyzes the conversion of estradiol to the less
active estrone, (iii) reduction in estrogen-induced specific
protein expression, and (iv) inhibition of estrogen-
induced proto-oncogenes (cjun, cfos), which act as
growth factors in the endometrium (reviewed by [9]).Page 2 of 12
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down-regulation of ER in target tissues most likely plays
the primary role in this respect.
During the drug discovery program, we conducted studies
in cynomolgus monkeys to determine the effects of
selected SPRMs in the primate endometrium [13]. One of
our initial studies compared the endometrial effects of a
"model" SPRM with high agonist activity (J1042) with
those of PAs (ZK 137 316 and ZK 230 211). This study
showed that all three compounds have a profound anti-
proliferative effect on the endometrium characterized by a
decrease in endometrial thickness and reduction in
mitotic activity in both endometrial epithelium and
stroma. Endometrial stroma appeared compact in all
treatment groups, which suggested a progesterone antago-
nist effect of J1042 and the reference PAs [9,18]. However,
J1042, but not the reference PAs, induced secretory activ-
ity of the endometrial glands characterized by glandular
sacculation with subnuclear vacuolization and secretion,
suggesting a weak progesterone agonistic effect. In con-
trast, both PAs produced degenerative changes in
endometrial glands without any secretory changes. In
addition, morphometric studies revealed that J1042
reduced intraluminal diameter of spiral arteries in the
basalis to a higher degree than the PAs, but did not cause
hyalinizing degeneration of spiral arteries as had previ-
ously been observed in animals treated with PAs. This
study, which showed for the first time the presence of par-
tial secretory effects of a SPRM in the primate
endometrium, played a key role in the conceptualization
and discovery of tissue selectivity of SPRMs.
Chronic toxicological studies conducted in intact
cynomolgus monkeys of 39-week duration consistently
showed endometrial antiproliferative effects of asoprisnil
[8] and asoprisnil ecamate (J956) (unpublished data). In
the 39-week toxicologic study, asoprisnil was adminis-
tered orally once daily to intact cynomolgus monkeys at
doses of 20, 60, 160 and 480 mg/kg/day. At these dosages,
the systemic drug exposure in female monkeys as area
under the plasma concentration curves (AUCs) combined
for the parent drug and J912, a major metabolite, were
1116, 5345, 16816 and 28838 ng•hr/mL, respectively.
Asoprisnil in the binding domain of the progesterone receptorFigu e 1
Asoprisnil in the binding domain of the progesterone receptor.Page 3 of 12
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amenorrhea and profound endometrial atrophy (early
proliferative stage) that was accompanied by a trend
towards more compact stromal appearance, without any
evidence of secretory changes in endometrial glands (Fig-
ure 4). This effect was observed in females of all asopris-
nil-treated groups (n = 4–5) except for females of the
highest dose group where the effect was observed in 4 of
the 5 females. Menstrual activity was suppressed in all aso-
prisnil-treated females within 2 weeks after the initiation
of treatment. Mean estradiol serum concentrations were at
early follicular levels.
The effect of asoprisnil on endometrial morphology was
consequently studied in more detail in cynomolgus mon-
keys treated with lower doses of asoprisnil for a shorter
period of time [19]. A total of 24 ovarian-intact, cycling
animals were administered either saline (n = 6) or vehicle
(n = 4) as controls, or three doses of asoprisnil (10 mg/kg
[n = 4], 30 mg/kg [n = 4] and 90 mg/kg [n = 6]) orally,
once daily for 90 days. Four animals from each group
were sacrificed at the end of treatment and two animals
from each of the saline and 90 mg/kg groups were held
without treatment for a recovery period of 28 days after
which they were also sacrificed. In this study, asoprisnil
was suspended in a vehicle containing 10% ethanol, 35%
PEG (polyethylene glycol) 300 and 55% Cremophor-EL
(polyoxyethylenglyceroltriricinoleat 35, polyoxyl 35 cas-
tor oil) to enhance its oral absorption. The AUCs at these
dosages in female monkeys were 368, 2495 and 13422
ng•hr/mL, respectively. The entire reproductive tract was
removed from all animals and assessed for general histo-
logical changes, including spiral artery development,
endometrial thickness, and stromal compaction.
Endometrial thickness was assessed by measuring the dis-
tance from the luminal surface to the myometrial border,
and stromal compaction was quantified by computerized
assessment of the number of stromal cells per unit area.
Chemical structures of major 11β-benzaldoxime substituted SPRMsFigure 2
Chemical structures of major 11β-benzaldoxime substituted SPRMs.
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ing two markers of proliferation, Ki-67 and phosphor-
ylated histone 3 (Phospho H3). Ki-67 is a nuclear protein
expressed during all stages of the cell cycle except G0 and
is a standard index of overall cellular proliferation.
Because histone 3 is phosphorylated only during mitosis
and is expressed only in mitotic chromosomes, Phospho
H3 staining provides a direct indication of mitotic activ-
ity[20]. The effects of asoprisnil on ovarian, cervical and
vaginal histology were also assessed.
In this study, the ovaries in the saline and vehicle controls
were all normal in appearance, marked by either antral
follicles or functional corpora lutea. The endometria in all
control animals were either in the proliferative or secre-
tory phases. However, in the asoprisnil-treated animals,
the two higher doses suppressed ovulation and progester-
one secretion. The previous 39-week toxicological study
showed that estradiol was maintained at follicular phase
levels, and in the current study, the vagina was in an estro-
genized state (assessed by degree of cornification) in all
asoprisnil-treated animals, indicating that (i) estradiol
levels were physiologically adequate, and (ii) asoprisnil
did not block estrogen action in the vagina.
However, all doses of asoprisnil significantly suppressed
the proliferation markers Ki-67 (Figure 5) and Phospho-
H3 (Figure 6) in the endometrial glands, and the two
higher doses caused significant shrinkage in endometrial
thickness (Figures 7, 8) without inducing progestational
effects such as glandular sacculation and secretion. There
was a trend for stromal compaction, but no evidence of
Spectrum of progesterone agonist and antagonist activities of major 11β-benzoxime-substituted SPRMs and PAsFigure 3
Spectrum of progesterone agonist and antagonist activities of major 11β-benzoxime-substituted SPRMs and 
PAs. The figure is based on studies in rabbits (McPhail test) and guinea pigs (luteolysis inhibition assay, induction of labor). 
ONA, onapristone; R520, pure progestin promegestone; J867, asoprisnil; PR, progesterone receptor. From [54] with permis-
sion.
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endometrial antiproliferative effect, but unlike a PA, did
not induce any severe stromal compaction or spiral artery
degeneration.
In sum, asoprisnil had reversible antiovulatory and
endometrial antiproliferative effects, but did not suppress
estrogen action in other parts of the reproductive tract of
ovarian-intact cynomolgus macaques.
Effects of asoprisnil on the human uterus
Phase I and Phase II trials confirmed tissue-selective
effects of asoprisnil in the human uterus. Some of the clin-
ical studies with asoprisnil have been published [10], or
reported in abstract form [11]; [21]; [12].
In a Phase I study, the effects of asoprisnil versus placebo
were evaluated in 60 healthy regularly cycling premeno-
pausal women during treatment for 28 days at daily oral
doses ranging from 5 mg to 100 mg/day, starting during
the first two days of the menstrual cycle [10]. Asoprisnil
consistently prolonged the menstrual cycle at doses ≥ 10
mg/day. However, the effects on luteal phase progester-
one indicative of luteinization were inconsistent and
lacked dose dependency. The estradiol levels of women
treated with asoprisnil were within the range of the follic-
ular phase. This study demonstrated that asoprisnil sup-
presses menstruation by primarily targeting the
endometrium.
In a Phase II setting, the effects of asoprisnil 5 mg, 10 mg,
and 25 mg on bleeding patterns and various leiomyoma
endpoints were evaluated in a double-blind, placebo-con-
trolled study of patients with uterine leiomyomata [11].
The patients were treated for 3 months. Asoprisnil signifi-
cantly suppressed both the duration and intensity of uter-
ine bleeding in a dose-dependent manner as evidenced by
bleeding diaries, and high amenorrhea rates (0%, 28.1%,
64.3%, and 83.3% at placebo, 5 mg, 10 mg and 25 mg,
respectively). There was a significant increase in hemo-
globin concentrations by week 12 in all asoprisnil groups
compared to placebo. Asoprisnil also significantly
reduced menorrhagia scores in patients with leiomyomata
[21]. The suppressive effects of asoprisnil on endometrial
bleeding were evident within the first month and main-
tained throughout the entire treatment period. These
effects were accompanied by a dose-dependent reduction
in the volumes of the largest leiomyoma as measured by
ultrasound. Asoprisnil had no statistically significant
effects on ovarian estrogens (estradiol and estrone). Con-
sistent with the absence of antiglucocorticoid activity in
humans at clinically relevant doses, there were no
increases in serum concentrations of cortisol or dehydroe-
The effects of asoprisnil on endometrial morphology in female cynomolgus monkeys (39-week toxicity study in adult cynomol-gus monkeys)Figure 4
The effects of asoprisnil on endometrial morphology in female cynomolgus monkeys (39-week toxicity study in 
adult cynomolgus monkeys). Photomicrographic comparison of glandular morphology in a control monkey during the 
secretory phase with an animal treated with asoprisnil at a dose of 20 mg/kg. Asoprisnil induced glandular atrophy. Magnifica-
tion 20×. From [8] with permission from Elsevier.Page 6 of 12
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S8piandrosterone sulphate (DHEA-S) with asoprisnil
[11,22].
In Phase I and II studies, the endometrial biopsies
obtained from women treated with asoprisnil studies
showed asynchronous differentiation of endometrial epi-
thelium and stroma consistent with its mixed progester-
one agonist/antagonist activity. These changes have not
been previously observed with any other hormonal treat-
ment. Furthermore, these biopsies could not be assessed
using the Noyes criteria of endometrial dating [23], as
originally planned. Therefore, an expert panel of gyneco-
logical pathologists in collaboration with Diagnostic
Cytology Laboratories, Indianapolis, IN, developed two
new diagnostic categories describing specific effects of
asoprisnil on the endometrium. The first category, "non-
physiologic secretory effect," is characterized by weak
secretory effects on endometrial glands without any
mitotic figures and variable effects on endometrial stroma
ranging from stromal compaction to focal predecidual
changes. The second category, "secretory pattern, mixed
type," differs from the first category by the presence of iso-
lated mitotic figures in endometrial glands. These appear-
ances were already evident after asoprisnil treatment for
28 days at doses of 5 mg and higher, and became more fre-
quent after treatment for 3 months [24]. The increase in
the frequency of non-physiologic secretory patterns was
accompanied with a decrease in proliferative patterns
[10]. Occasionally, dilated glands filled with secretory
material and covered by inactive epithelium were
Asoprisnil suppresses the Ki-67 index in cynomolgus macaque endom triumFigu e 5
Asoprisnil suppresses the Ki-67 index in cynomolgus 
macaque endometrium. All doses of asoprisnil inhibited 
endometrial Ki-67 index compared to control animals in the 
proliferative phase of the cycle. Bars marked with an asterisk 
are significantly different from all other bars (p < 0.05).
Asoprisnil suppresses the Phospho H3 index in cynomolgus macaque endom triumFigu e 6
Asoprisnil suppresses the Phospho H3 index in 
cynomolgus macaque endometrium. All doses of aso-
prisnil inhibited endometrial Phospho-H3 index compared to 
control animals in the proliferative phase of the cycle. Bars 
marked with an asterisk are significantly different from all 
other bars (p < 0.05).
Effect of asoprisnil on overall endometrial histologyFigure 7
Effect of asoprisnil on overall endometrial histology. 
Photomicrographic comparison of endometrial histology of 
typical control animals (proliferative and secretory phases) 
versus asoprisnil-treated (90 mg/kg) animals. Original magnifi-
cation ~4×.Page 7 of 12
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Interestingly, clusters of unusual "thick-walled" arterial
vessels were consistently found in the endometrium of
women treated with asoprisnil (Figure 9). This effect is
specific to the endometrium since no changes in the wall
of arterial vessels were found in non-endometrial tissues
of the reproductive tract [24].
In summary, asoprisnil demonstrated antiproliferative
effects on the endometrium in the presence of follicular
phase estradiol concentrations in both humans and mon-
keys. However, these studies also revealed some differ-
ences between the non-human primate models and
humans with respect to endometrial effects. In the human
endometrium, asoprisnil treatment for up to 3 months
was associated with non-physiologic secretory effects in
the glandular epithelium and presence of unusual "thick-
walled" arterial vessels in the stroma [24]. In cynomolgus
monkeys neither secretory changes in endometrial glands,
nor formation of thick-walled endometrial spiral arteries
were observed, pointing out to some important differ-
ences in the steroid receptor pharmacology of the monkey
and human endometrium. The reason for these differ-
ences is unclear. However, our studies with asoprisnil and
previous experience with PAs suggest that the macaque
endometrium might be more sensitive to PR-ligands than
the human endometrium, which would explain more dra-
matic effects of SPRMs and PAs in these animals. There-
fore, in spite of many similiarities between monkey and
human endometrium, caution is warranted in extrapolat-
ing the data generated in nonhuman primates to humans.
Effects of SPRMs on the breast tissue in 
cynomolgus monkeys
The potential effects of SPRMs on the breast tissue are of
special interest. In primates, mammary gland develop-
ment is controlled by a complex interplay between the
reproductive hormones (estradiol, progesterone, and pro-
lactin), and local growth factors [25]. There is growing evi-
dence that progesterone is an important mitogen in
epithelial breast cells [26]. On the one hand, PAs suppress
mammary gland proliferation and inhibit growth of PR-
positive mammary gland tumors in animal models [27].
On the other hand, mitotic activity in normal breast tissue
peaks during the luteal phase, and synthetic progestins
consistently increase mammographic breast density,
which is a surrogate parameter of breast proliferation
[28,29], as well as upregulate the expression of prolifera-
tion markers in the mammary gland [30].
Inhibitory effects of asoprisnil on mammary gland devel-
opment were consistently observed in a 39-week toxico-
logical study in intact female cynomolgus monkeys [31].
Although these effects are consistent with antiproliferative
effects of asoprisnil on mammary gland proliferation,
they should be interpreted with caution because of high
doses used in toxicological studies, and potential differ-
ences between macaques and humans regarding hormo-
nal regulation of breast proliferation and differentiation.
Mechanism of tissue selectivity of SPRMs
Our studies in non-human primates and humans
reviewed above revealed that asoprisnil and other 11β-
benzaldoxime-substituted SPRMs exert tissue-selective
effects on the uterus in the presence of follicular phase
estrogen concentrations and no antiglucocorticoid effects.
These compounds can abolish endometrial bleeding and
suppress endometrial proliferation in both macaques and
humans. Inhibitory effects of leiomyoma growth were
observed in human studies with asoprisnil. Our studies
show that asoprisnil exhibits inhibitory effects on (i)
endometrial bleeding, (ii) endometrial proliferation, and
(iii) leiomyoma volume in humans, predominantly via
tissue-specific (uterine) mechanisms. These effects, dis-
cussed in more detail below, are likely to reflect target tis-
sue specific manifestation of PR modulation that affects
downstream pathways of PR, ER AR and most likely other,
still unidentified pathways.
Control of endometrial bleeding
Amenorrhea was consistently observed in asoprisnil-
treated cynomolgus monkeys [8]. In women, amenorrhea
Effects of asoprisnil on endometrial thicknessFigure 8
Effects of asoprisnil on endometrial thickness. The 
two higher doses of asoprisnil significantly inhibited endome-
trial thickness compared to all other groups. Bars marked 
with an asterisk are significantly different from all other bars 
(p < 0.05).Page 8 of 12
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Representative endometrial biopsies of subjects treated with asoprisnil for 28 days. The photographs show examples consist-ent with the diag osis "non-physiologic ecr tory ffect"Figure 9
Representative endometrial biopsies of subjects treated with asoprisnil for 28 days. The photographs show exam-
ples consistent with the diagnosis "non-physiologic secretory effect". a: Weakly secretory glands with vacuoles below nuclei 
(solid arrow; Subject MN-6; asoprisnil 10 mg QD); b: Thick-walled vessels (open arrow; Subject MN-6; asoprisnil 10 mg); c: 
Mild to moderate secretory glands at low magnitude. Note area of relatively dense stroma. (subject MN, 25 mg BID); d: Mod-
erate secretory glands with subnuclear vacuoles at higher magnitude (solid arrow; subject MN, 25 mg BID). QD, once a day. 
BID, twice a day. From [10] with permission.
Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S8was already observed within 30 days of commencement
of asoprisnil treatment, irrespective of the effect of lutein-
ization suggestive of ovulation. This effect is sustained
during longer treatment, with minimal bleeding abnor-
malities such as spotting and breakthrough bleeding
[10,11]. These observations suggest that the endometrial
arteries are stable during treatment with asoprisnil.
Although the mechanism of asoprisnil-induced amenor-
rhea is still not completely understood, the current evi-
dence suggests that asoprisnil may have a direct or indirect
inhibitory effect on endometrial spiral arteries. Interest-
ingly, asoprisnil-induced morphological changes in spiral
arteries, characterized by thickening of the wall, clearly
differ from those commonly observed in women using
long-acting progestins or levonorgestrel-containing intra-
uterine systems. These treatments are associated with the
formation of "thin-walled" microvessels that are very frag-
ile, and frequently lead to breakthrough bleeding [32-34].
Our working hypothesis is that asoprisnil controls
endometrial bleeding by targeting the perivascular cells in
the endometrium, which are characterized by a high den-
sity of PRs [17]. This hypothesis, which is currently under
investigation, would explain tissue-specific effects of aso-
prisnil on endometrial vasculature.
Endometrial antiproliferative effect
Asoprisnil and structurally related SPRMs have endome-
trial antiproliferative effects in macaques and humans.
The exact mechanism of this effect is still not fully under-
stood. The effects of asoprisnil on the human
endometrium are currently being investigated using vari-
ous morphological, immunohistochemical and molecu-
lar endpoints. These studies should provide more insight
into the molecular mechanisms underlying this effect, in
particular the role of the partial progesterone agonist and
antagonist activities of asoprisnil in the endometrium.
Based on experiments conducted in cynomolgus mon-
keys, we previously proposed that the endometrial anti-
proliferative effect of SPRM and PAs might be due to the
reduction in endometrial blood flow as consequence of
vascular changes in the endometrium [9]. However, this
hypothesis has not yet been confirmed in humans. More
recently the role of endometrial AR has been emphasized
as a potential mechanism of the endometrial antiprolifer-
ative effects of PAs [35-38]. Androgens are known to
inhibit estrogen effects in the primate endometrium [38].
The AR hypothesis was proposed based on the observa-
tion of greatly enhanced expression of AR in the endome-
trial glands of macaques treated with various PAs and in
women treated with mifepristone [35]. Furthermore, the
AR antagonist flutamide reversed the endometrial anti-
proliferative effect of the PA as evidenced by changes in
mitotic index, endometrial height and weight [39]. Since
up-regulation of AR was observed in the endometrial
stroma of cynomolgus monkeys treated with asoprisnil,
its antiproliferative effect on endometrial glandular epi-
thelium might be mediated by AR-mediated stromal
growth factors [19]. In addition, asoprisnil has weak
androgenic properties, which may play a role in this
respect [8].
Reduction in leiomyoma volume
Several mechanisms, which are under investigation,
might be involved in asoprisnil-induced reduction in lei-
omyoma volume, including a direct, PR-mediated anti-
proliferative and pro-apoptotic effects on leiomyoma
cells, inhibition of growth factors, modulation of extracel-
lullar matrix synthesis, reduction in uterine blood flow,
etc.
The results of an in vitro study with leiomyoma and myo-
metrial primary cell cultures showed that asoprisnil inhib-
its proliferation and induces apoptosis of leiomyoma cells
without having any effects on the normal myometrial
cells [40]. In this study, the proliferation marker PCNA
was used to quantify the effects on proliferation, whereas
TUNEL assay was used to determine the effects on apop-
tosis. In a second study, asoprisnil also inhibited the
expression of EGF, IGF-I, TGFβ3 and their receptors in cul-
tured leiomyoma cells without affecting their expression
in matching myometrial cells [41]. In addition, a decrease
in uterine blood flow following treatment with asoprisnil
may contribute to this effect. This hypothesis is currently
under evaluation in clinical studies.
Molecular basis for tissue-selective effect of SPRMs
The molecular mechanism of tissue selectivity of steroid
receptor modulators has been recently proposed based on
the ability of a liganded PR to interact with different coreg-
ulators depending on the specific ligand [42-45]. Coregu-
lators (coactivators and corepressors) are nuclear proteins
that form multiple complexes with nuclear receptors and
modulate their transcriptional activity [46-49]. Coactiva-
tors enhance transcriptional activity of nuclear receptors,
whereas corepressors elicit inhibitory effects on nuclear
receptors. The PAs either favor interaction of PR with core-
pressors or inhibit interactions with coactivators, whereas
"pure" PR agonists promote the interaction of the nuclear
receptor with coactivators [50,51]. SPRMs with partial PR
agonist activity induce an intermediate state of interaction
between nuclear receptors and coactivators [45,50,52].
Since the availability of both coactivators and corepres-
sors is dependent on tissue and hormonal milieu, the cell
type- and promoter-specific differences in coregulator
recruitment determine the tissue selectivity of SPRMs
[6,45]. More recent molecular studies show that asopris-
nil-liganded PR promotes the recruitment of the coactiva-
tor SRC-1 in an in vitro model [53] which could explain
the partial agonist effects observed in animal models andPage 10 of 12
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human tissues exposed to asoprisnil are ongoing. These
studies should provide more insight into the molecular
mechanism of tissue selectivity of asoprisnil in the uterus.
Summary and Conclusion
Studies in non-human primates played a key role in the
conceptualization and discovery of tissue selectivity of
SPRMs. They provided the first evidence of the endome-
trial antiproliferative effects of asoprisnil and other 11β-
benzaldoxime substituted SPRMs in the primate model,
as characterized by a decrease in mitotic counts, Phospho
H3 expression and endometrial thickness. These models
also showed that PR modulation results in a complex
interaction with ER- and AR-mediated responses. Uterus-
selective effects of asoprisnil have been confirmed in clin-
ical studies in humans. Clinical studies in healthy volun-
teers (Phase I) and patients with leiomyomata showed
that asoprisnil induces dose-dependent inhibition of uter-
ine bleeding predominantly due to an endometrial effect.
Furthermore, our Phase II studies showed that asoprisnil
reduces the volume of uterine leiomyomata in a dose-
dependent manner. Although the mechanism of this
effect is not fully explored, the in vitro studies with leio-
myoma primary cell cultures, as well as morphological
investigations of leiomyoma tissue suggest a increase in
apoptosis accompanied by a decrease in proliferation after
treatment with asoprisnil. These effects seem to be cell-
specific, since no such changes were observed in myome-
trial cells.
Asoprisnil induces "non-physiologic secretory effects" on
the human endometrium during treatment for up to 3
months. These effects are consistent with endometrial
antiproliferative effects of asoprisnil, without evidence of
hyperplastic changes. However, long-term studies with
asoprisnil will be necessary to fully assess the endometrial
effects of asoprisnil.
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